Compare AbbVie Inc (ABBV) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Synopsys, Inc. — how do they compare? AbbVie Inc trades at $248.25 (market cap $441.94B), while Synopsys, Inc. trades at $413 (market cap $78.68B). The key difference: AbbVie Inc is far larger — about 5.6× Synopsys, Inc.'s market cap, and AbbVie Inc pays a 2.77% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| ABBV | SNPS | |
|---|---|---|
Market Cap | $441.94B | $78.68B |
Sector | Health | Technology |
52-Week High | $263.58 | $625.80 |
52-Week Low | $197.38 | $372.33 |
Enterprise Value | $506.19B | $87.04B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
Synopsys (SNPS) trades at $411.68, down 1.04% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish overall signal despite recent volatility, with strong analyst support (82.76% buy ratings) and a consensus price target of $551.00. Recent earnings beats and strategic moves like the Ansys acquisition highlight robust growth prospects in the semiconductor design software space, though high valuation multiples and significant cash flow volatility warrant caution.
The outlook for SNPS remains positive driven by AI-driven demand and recurring revenue streams, but investors face risks from elevated valuations, integration challenges from acquisitions, and semiconductor cycle sensitivity. The stock's current price near key support levels offers a potential entry point for long-term growth investors, contingent on sustained execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
